Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print The G allele of the mu-opioid receptor gene is linked to craving for alcohol

The G allele of the mu-opioid receptor gene is linked to craving for alcohol

January 04, 2007

- Alcohol-use disorders have a significant genetic component to their development.
- New findings show that heavy drinkers with the G allele of the A118G polymorphism of the mu-opioid receptor gene have greater cravings after alcohol exposure than heavy drinkers homozygous for the A allele.
- Individuals with the G allele may have more problems resisting the urge to drink.

The study of genes and their influence on alcohol consumption can operate on many different levels. Some studies examine how genes may interact with the environment, some look specifically at family history of alcohol dependence, and some zero in on "pieces" of genes and their influence on drinking. A new study has found that individuals carrying a G allele of the A118G polymorphism of the mu-opioid receptor gene (OPRM1) crave alcohol more than individuals with the more common A allele.




Results are published in the January issue of Alcoholism: Clinical & Experimental Research.

"The more sensitive mu-opioid receptor in individuals carrying a G allele of the A118G polymorphism may lead to different behavioral responses due to a different physiological functioning of the receptor," explained Esther van den Wildenberg, a researcher at the University of Maastricht and corresponding author for the study. "Beta-endorphins are released upon alcohol or drug intake. Different receptor functioning could affect functions such as drug-induced euphoria and analgesia which might influence the subjective experience of the drug and subsequent use."

Van den Wildenberg added that people may not realize that exposure to alcoholic cues is very common in society, for example, in supermarkets, on television, in bars, on billboards, in magazines, etc.

"We were interested whether heavy drinking individuals - in other words, not yet alcohol dependent - carrying a copy of the G allele would respond differently than 'standard' genotype individuals when exposed to alcohol cues," she said.

"If the G allele affects subjective experience such as craving for alcohol after exposure, this could also have an influence on subsequent drinking behavior. It turns out that G allele carriers do crave significantly more for alcohol after alcohol exposure, compared with the A allele individuals."

"Studies like this one are important in terms of saying something about how a gene might be involved in alcohol dependence," said Kent Hutchison, associate professor at the University of Boulder, Colorado. "In this case, the study suggests that this genetic marker may be related to how much a person craves alcohol in a high-risk situation, that is, when someone hands him or her an alcoholic drink. At this point in time, this gene definitely seems to be one of the key genes related to alcohol dependence. There will undoubtedly be others."

Researchers recruited 108 male, heavy drinkers via flyers in and around the University of Maastricht. Participants were either homozygous for the A allele (n=84) or carrying at least one copy of the G allele (n=24). All participated in a cue-reactivity test where they were exposed to water and beer in three-minute trials. Dependent variables included subjective craving for alcohol, subjective arousal, and saliva production.

"By looking at cue-elicited craving in heavy drinkers, we look more specifically into a so-called 'endophenotype,'" explained van den Wildenberg. An endophenotype, she said, is like an intermediate phenotype. It lies "between" the genotype, referring to genes, and the phenotype, which refers to the disorder; reflecting a biological mechanism that underlies the disorder.

"Not only did G allele carriers report even significantly more craving for alcohol than the A allele individuals," said van den Wildenberg, "but G allele carriers reported more life-time drug use compared with the 'standard' genotype participants. Especially the use of cannabis and amphetamines."

"The primary finding is important because individuals who are more prone to cue-induced craving may also be more prone to relapse in a high-risk situation," said Hutchison. "In other words, alcoholics with the G allele who are trying to remain abstinent may have more difficulty than alcoholics without the G allele." The secondary finding - of greater other-drug use among individuals in the G-allele group - is less conclusive, he said.

"The problem is that there are many reasons why people use drugs," he noted. "This genetic marker may influence some of the variables that lead to drug use, but there are many other variables that are not related to this gene. This is part of the reason that there are inconsistencies in the scientific literature."

Nonetheless, both van den Wildenberg and Hutchison noted the importance for treatment options of identifying "risk genes" that predispose certain individuals to alcohol-problems. "Eventually, knowledge about the genetic variables that influence alcohol abuse may be used to help determine which treatment is most appropriate for a given individual," said Hutchison. "For example, an individual who has a gene that confers some vulnerability in a particular system in the brain may benefit most from a treatment that targets this vulnerability."

"In this case," added van den Wildenberg, "patients with a G allele of the mu-opioid receptor gene might benefit from "¦the anti-craving medication naltrexone, which blocks the mu-opioid receptor. Naltrexone has been found to work especially well in alcohol-dependent patients with a G allele, possibly due to a stronger decrease in craving in these individuals."

Alcoholism: Clinical & Experimental Research



Related Opioid Receptor Current Events and Opioid Receptor News Articles Opioid Receptor Current Events and Opioid Receptor News RSS Opioid Receptor Current Events and Opioid Receptor News RSS
Common pain relief medication may encourage cancer growth
Although morphine has been the gold-standard treatment for postoperative and chronic cancer pain for two centuries, a growing body of evidence is showing that opiate-based painkillers can stimulate the growth and spread of cancer cells.

Stress-induced changes in brain circuitry linked to cocaine relapse
Stress-evoked changes in circuits that regulate serotonin in certain parts of the brain can precipitate a low mood and a relapse in cocaine-seeking, based on mouse studies published online this week in the Proceedings of the National Academy of Sciences.

Researchers find genetic link between physical pain and social rejection
UCLA psychologists have determined for the first time that a gene linked with physical pain sensitivity is associated with social pain sensitivity as well.

Study first to pinpoint why analgesic drugs may be less potent in females than in males
Investigators at Georgia State University's Neuroscience Institute and Center for Behavioral Neuroscience are the first to identify the most likely reason analgesic drug treatment is usually less potent in females than males.

Opioids and cannabinoids influence mobility of spermatozoids
A PhD thesis from the University of the Basque Country has concluded that there are opioid and cannabinoid receptors in human sperm and that these influence the mobility of spermatozoid.

Gene variant predicts medication response in patients with alcohol dependence
Patients with a certain gene variant drank less and experienced better overall clinical outcomes than patients without the variant while taking the medication naltrexone, according to an analysis of participants in the National Institutes of Health's 2001-2004 COMBINE (Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence) Study.

How does the opioid system control pain, reward and addictive behavior?
The opioid system controls pain, reward and addictive behaviors. Opioids exert their pharmacological actions through three opioid receptors, mu, delta and kappa whose genes have been cloned (Oprm, Oprd1 and Oprk1, respectively).

Why don't painkillers work for people with fibromyalgia?
People who have the common chronic pain condition fibromyalgia often report that they don't respond to the types of medication that relieve other people's pain.

Potential new pain killer drug developed by scientists at Leicester and Italy
A potential new pain-killing drug developed by medical scientists at the University of Leicester and Ferrara in Italy is to be discussed at a public lecture on 20th March.

Study advances evidence for receptor's role in alcohol pleasure and problems
A genetic variant of a receptor in the brain's reward circuitry heightens the stimulating effects of early exposures to alcohol and increases alcohol consumption, according to a new study by researchers at the National Institute on Alcohol Abuse and Alcoholism (NIAAA), part of the National Institutes of Health (NIH).
More Opioid Receptor Current Events and Opioid Receptor News Articles
  Old drugs in new role: relieving chronic pruritus; Cannabinoid agonists, opioid receptor antagonists have attracted the attention of dermatologists.(Across ... An article from: Clinical Psychiatry News
by Patrice Wendling (Author)

This digital document is an article from Clinical Psychiatry News, published by Thomson Gale on December 1, 2005. The length of the article is 584 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: Old drugs in new role: relieving chronic pruritus; Cannabinoid agonists, opioid receptor antagonists have attracted the attention of dermatologists.(Across Specialties)
Author: Patrice Wendling
Publication: Clinical Psychiatry News (Magazine/Journal)
Date: December 1, 2005
Publisher: Thomson Gale
Volume: 33 Issue: 12 Page: 63(1)

Distributed by Thomson...

  ADOLOR SUBMITS ADL5747 IND FOR DELTA OPIOID RECEPTOR TARGET.: An article from: Biotech Business
by Gale Reference Team (Author)

This digital document is an article from Biotech Business, published by Thomson Gale on February 1, 2008. The length of the article is 425 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.

Citation Details
Title: ADOLOR SUBMITS ADL5747 IND FOR DELTA OPIOID RECEPTOR TARGET.
Author: Gale Reference Team
Publication: Biotech Business (Newsletter)
Date: February 1, 2008
Publisher: Thomson Gale
Volume: 21 Issue: 2 Page: NA

Distributed by Thomson...

Deletion of the mu opioid receptor results in impaired acquisition of Pavlovian context fear [An article from: Neurobiology of Learning and Memory]

Deletion of the mu opioid receptor results in impaired acquisition of Pavlovian context fear [An article from: Neurobiology of Learning and Memory]
by M.J. Sanders (Author), B.L. Kieffer (Author), M.S. Fanselow (Author)

This digital document is a journal article from Neurobiology of Learning and Memory, published by Elsevier in . The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.

Description:
The mu opioid receptor may constitute a critical component of a negative feedback system that regulates Pavlovian fear conditioning. We investigated context fear conditioning acquisition and expression in mu opioid receptor knockout mice (on an inbred, C57 genetic background). We discovered that the mu receptor knockout results in an unexpected and significant deficit in context fear acquisition. Mice lacking the mu receptor showed normal fear acquisition when subjected to a 1-day fear conditioning...

  The role of progestin receptors and the mitogen-activated protein kinase pathway in @d opioid receptor facilitation of female reproductive behaviors [An article from: Hormones and Behavior]
by M. Acosta-Martinez (Author), O. Gonzalez-Flores (Author), A.M Etgen (Author)

This digital document is a journal article from Hormones and Behavior, published by Elsevier in 2006. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.

Description:
The present study investigated the role of the progestin receptor (PR) and the mitogen-activated protein kinase (MAPK) pathway in the facilitation of lordosis behavior by the @d opioid receptor agonist [d-Pen^2, d-Pen^5]-enkephalin (DPDPE). Ovariectomized, estrogen-primed rats were treated with the PR antagonist RU486 or the MAPK inhibitor PD98059 prior to intraventricular (icv) infusion of DPDPE. Both RU486 and PD98059 blocked receptive and proceptive behaviors induced by DPDPE at 60 min, and RU486 continued to...

  Opioids and Opioid Receptors (Journal of Biomedical Science)
by L. F. Tseng (Editor), J. M. Fujimoto (Editor), Ing K. Ho (Editor), Jean Yu-Wen Shen Wu (Editor)



  OPIATES/OPIOIDS: An entry from Macmillan Reference USA's Encyclopedia of Drugs, Alcohol and Addictive Behavior
by GAVRIL W. PASTERNAK (Author), REBECCA MARLOW-FERGUSON (Author)

This second edition of the “Encyclopedia of Drugs, Alcohol, and Addictive Behavior†reflects changes in the attitudes about, use, and knowledge of drugs and alcohol since the first edition published in 1995. These changes include the decrease of crack cocaine use and resurgence of heroin use; changes in laws dealing with drug use (on both the state and national levels), and new discoveries leading to a better understanding of how drugs work and what makes them addictive. More than 700 articles, written for both the student and layperson, cover the social, medical and political issues related to drugs and alcohol, as well exploring and explaining types of addiction.



  Endogenous opioids and their receptors (Current concepts)
by John W Holaday (Author)



  Opioid Sensitivity of Chronic Noncancer Pain (Progress in Pain Research and Management, V. 14)
by Eija, Ph.D. Kalso (Editor), Henry J. McQuay (Editor), Zsuzsanna Wiesenfeld-Hallin (Editor), International Association for the Study of Pain Research Symposium 199 (Editor)



The Delta Receptor

The Delta Receptor
by Kwen-Jen Chang (Editor), Frank Porreca (Editor), James Woods (Editor)

Presents mixed opioid receptor agonists as a new class of agents for the treatment of moderate-to-severe pain. Key topics include cloning and expression of the human delta opioid receptor.

  New Leads in Opioid Research: International Conference Proceedings (International congress series)
by Jan M.Van Ree (Editor), etc. (Editor)



© 2009 BrightSurf.com